I agree that this site is using cookies. You can find further informations here.
X
Sandborn, William
1366  results:
Search for persons X
?
1

905 DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDO..:

Jairath, Vipul ; Zou, GY ; Adsul, Shashi...
Gastroenterology.  166 (2024)  5 - p. S-218 , 2024
Link: https://doi.org/10.1016/..
 
?
2

987 EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1..:

Sands, Bruce E. ; Panaccione, Remo ; D'Haens, Geert...
Gastroenterology.  166 (2024)  5 - p. S-240 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled..:

Ghosh, Subrata ; Feagan, Brian G ; Ott, Elyssa...
Journal of Crohn's and Colitis.  , 2024
Link: https://doi.org/10.1093/..
 
?
4

Determining the optimal treatment target in patients with u..:

Jairath, Vipul ; Zou, Guangyong ; Wang, Zhongya...
BMJ Open Gastroenterology.  11 (2024)  1 - p. e001218 , 2024
Link: https://doi.org/10.1136/..
 
?
5

Pangenome comparison ofBacteroides fragilisgenomospecies un..:

Oles, Renee E. ; Carrillo Terrazas, Marvic ; Loomis, Luke R....
mSystems.  , 2024
Link: https://doi.org/10.1128/..
 
?
6

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN O..:

Danese, Silvio ; Colombel, Jean-Frederic ; Hanauer, Stephen...
Inflammatory Bowel Diseases.  30 (2024)  Supplement_1 - p. S00-S00 , 2024
Link: https://doi.org/10.1093/..
 
?
7

Evolution of Symptoms After Ustekinumab Induction Therapy i..:

Colombel, Jean-Frédéric ; Sands, Bruce E. ; Gasink, Christopher...
Clinical Gastroenterology and Hepatology.  22 (2024)  1 - p. 144-153.e2 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Reliability and Responsiveness of Clinical and Endoscopic O..:

Khanna, Reena ; Feagan, Brian G ; Zou, Guangyong...
Inflammatory Bowel Diseases.  , 2024
Link: https://doi.org/10.1093/..
 
?
9

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXI..:

Schreiber, Stefan ; Colombel, Jean-Frederic ; Hanauer, Stephen...
Inflammatory Bowel Diseases.  30 (2024)  Supplement_1 - p. S8-S9 , 2024
Link: https://doi.org/10.1093/..
 
?
10

Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE C..:

Sandborn, William J. ; Sands, Bruce E. ; Hanauer, Stephen B....
Gastroenterology.  166 (2024)  5 - p. S-810 , 2024
Link: https://doi.org/10.1016/..
 
?
11

Su1762 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE T..:

Hanauer, Stephen B. ; Colombel, Jean Frederic ; Sandborn, William J....
Gastroenterology.  166 (2024)  5 - p. S-802 , 2024
Link: https://doi.org/10.1016/..
 
?
12

Achievement of Clinical, Endoscopic, and Histological Outco..:

Yarur, Andres J ; Chiorean, Michael V ; Panés, Julián...
Journal of Crohn's and Colitis.  18 (2024)  6 - p. 885-894 , 2024
Link: https://doi.org/10.1093/..
 
?
13

A global consensus on the definitions, diagnosis and manage..:

Bettenworth, Dominik ; Baker, Mark E. ; Fletcher, Joel G....
Nature Reviews Gastroenterology & Hepatology.  , 2024
Link: https://doi.org/10.1038/..
 
?
14

Efficacy of vedolizumab during intravenous induction therap..:

D'Haens, Geert ; Baert, Filip ; Danese, Silvio...
European Journal of Gastroenterology & Hepatology.  36 (2024)  4 - p. 404-415 , 2024
Link: https://doi.org/10.1097/..
 
?
15

Exposure–efficacy relationship of vedolizumab subcutaneous ..:

D'Haens, Geert ; Rosario, Maria ; Polhamus, Daniel...
Expert Review of Clinical Pharmacology.  17 (2024)  4 - p. 403-412 , 2024
Link: https://doi.org/10.1080/..
 
1-15